Drug development – Page 21

Reproducibility gaps during study audit – preventing clinical hold

Addressing Gaps in Reproducibility During Study Audits to Avoid Clinical Holds In the realm of pharmaceutical research and drug development, reproducibility is paramount to securing regulatory approvals and ensuring robust…

GLP readiness concerns during study audit – how to defend preclinical package

Addressing GLP Readiness Issues During Audit: A Strategic Investigation During preclinical studies, Good Laboratory Practice (GLP) compliance is paramount to ensure regulatory acceptance and successful drug discovery. However, GLP readiness…

Study design not regulator-aligned during study audit – FDA/EMA non-clinical expectations

Identifying Misalignment in Study Design During Regulatory Audits Regulatory audits during preclinical studies often reveal critical gaps in study designs that do not align with official requirements from the FDA…

Dose justification weak during regulatory submission prep – FDA/EMA non-clinical expectations

Investigating Weak Dose Justification in Regulatory Submission Preparations The preparation for regulatory submissions can often expose weaknesses in dose justification during the preclinical development phase, particularly under scrutiny from agencies…

Species selection questioned during IND-enabling studies – FDA/EMA non-clinical expectations

Investigating Species Selection Concerns in IND-Enabling Studies for Regulatory Compliance In the intricate landscape of drug development, the species selection in IND-enabling studies has become a focal point for scrutiny.…

Species selection questioned during regulatory submission prep – FDA/EMA non-clinical expectations

Investigating Species Selection Issues During Regulatory Submission Preparation In the realm of pharmaceutical development, regulatory submissions play a pivotal role in determining the fate of a drug candidate. A common…

Non-clinical toxicity findings during study audit – how to defend preclinical package

Addressing Non-Clinical Toxicity Findings during Study Audits to Support Preclinical Packages In the realm of pharmaceutical development, the identification of non-clinical toxicity findings during study audits can raise significant concerns…

Study design not regulator-aligned during sponsor oversight – preventing clinical hold

Investigation into Misalignment of Study Design with Regulatory Expectations During Sponsor Oversight In the complex landscape of pharmaceutical research and drug development, achieving alignment between study design and regulatory expectations…

Study design not regulator-aligned during sponsor oversight – CAPA for study design gaps

Addressing Study Design Misalignments with Regulatory Expectations in Sponsor Oversight The pharmaceutical industry faces numerous challenges in preclinical research, particularly in ensuring that study designs align with regulatory expectations set…

GLP readiness concerns during program hold risk review – how to defend preclinical package

Addressing GLP Readiness Issues During a Program Hold Risk Review In the dynamic world of pharmaceutical development, holding a program due to GLP (Good Laboratory Practice) readiness concerns can pose…

Non-clinical toxicity findings during study audit – CAPA for study design gaps

Addressing Non-clinical Toxicity Issues Uncovered During Audit: A Structured CAPA Process In the complex landscape of preclinical research, unexpected non-clinical toxicity findings can arise during an audit, escalating into a…

Species selection questioned during program hold risk review – preventing clinical hold

Addressing Species Selection Issues During Program Hold Risk Review During the drug development process, particularly in preclinical studies, questions about species selection can lead to significant program holds. These holds…